Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04842266 · ClinicalTrials.gov registry record

IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures

A clinical trial of Trauma and Cancer Metastatic, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT04842266: Recruiting study of Trauma and Cancer Metastatic, sponsored by Massachusetts General Hospital.

NCT04842266 is a study of Trauma and Cancer Metastatic that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 306-participant average among 56 other Trauma trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04842266, a study of Trauma and Cancer Metastatic, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

The aim of this project is to assess the effectiveness of the IlluminOss pelvic implants in patients with pelvic metastatic disease presenting with pain, risk of pathologic fracture, non-displaced or minimally displaced pathologic fracture of the pelvis, and geriatric patients with pelvic fragility fractures. Results from this study will be used to confirm preliminary clinically and possibly statistically significant reductions in pain and improvements in function among these patients.

Primary Outcome

Patients treated with the IlluminOss pelvic implant will be given functional and pain surveys pre-operatively (within 2 weeks before surgery) and post-operatively (at 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 1 year, and 2 years). 100 patients will be included in the study. The surveys include the VAS Pain, the EQ-VAS, the Combined Pain and Ambulatory Function, the PROMIS Pain Inteference, and the PROMIS Physical Function. Additionally, the MSTS survey will be collected for oncologic patient

Interventions

  • DEVICE IlluminOss pelvic implant for oncologic indication
  • DEVICE IlluminOss pelvic implant for geriatric trauma indication

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-11-18
Est. Completion 2027-12
Massachusetts General Hospital

2,032 total trials

What NCT04842266 shows while recruiting

NCT04842266 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 306-participant average among 56 other Trauma trials with a reported enrollment target (67% lower).

The record links to 3 conditions, with Trauma appearing as the primary indexed condition, and to 2 interventions - of which IlluminOss pelvic implant for oncologic indication is the first listed.

NCT04842266 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04842266 about?

NCT04842266 is a clinical study titled "IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures". The aim of this project is to assess the effectiveness of the IlluminOss pelvic implants in patients with pelvic metastatic disease presenting with pain, risk of pathologic fracture, non-displaced or minimally displaced pathologic fracture of the pelvis, and geriatric patients with pelvic fragility ...

What is the current status of trial NCT04842266?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2021-11-18. Estimated completion is 2027-12.

What conditions does trial NCT04842266 study?

This clinical trial studies the following conditions: Trauma, Cancer Metastatic, Pathologic Fracture.

What interventions are being tested in trial NCT04842266?

The interventions under investigation include: IlluminOss pelvic implant for oncologic indication (DEVICE), IlluminOss pelvic implant for geriatric trauma indication (DEVICE).

Who is sponsoring clinical trial NCT04842266?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04842266 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Trauma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04842266's enrollment target sits among peer trials

100 31st of 56 higher than 25 of 56 other Trauma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Trauma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04842266, the US trial registry maintained by the National Library of Medicine. NCT04842266 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.